The estimated Net Worth of Daniel C. Martin is at least $2.64 Million dollars as of 15 February 2024. Mr Martin owns over 2,267 units of Deciphera Pharmaceuticals Inc stock worth over $1,410,470 and over the last 6 years he sold DCPH stock worth over $526,645. In addition, he makes $707,823 as Sr. VP & Chief Commercial Officer at Deciphera Pharmaceuticals Inc.
Mr has made over 12 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,267 units of DCPH stock worth $35,411 on 15 February 2024.
The largest trade he's ever made was exercising 26,999 units of Deciphera Pharmaceuticals Inc stock on 22 January 2020 worth over $974,664. On average, Mr trades about 3,830 units every 101 days since 2018. As of 15 February 2024 he still owns at least 55,118 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr Martin stock trades at the bottom of the page.
Daniel C. Martin is the Sr. VP & Chief Commercial Officer at Deciphera Pharmaceuticals Inc.
As the Sr. VP & Chief Commercial Officer of Deciphera Pharmaceuticals Inc, the total compensation of Mr Martin at Deciphera Pharmaceuticals Inc is $707,823. There are 12 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Mr Martin is 46, he's been the Sr. VP & Chief Commercial Officer of Deciphera Pharmaceuticals Inc since . There are 19 older and 1 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: